ProfileGDS5678 / 1425354_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 89% 89% 90% 89% 86% 87% 88% 87% 88% 88% 90% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8062988
GSM967853U87-EV human glioblastoma xenograft - Control 26.9984789
GSM967854U87-EV human glioblastoma xenograft - Control 37.0348889
GSM967855U87-EV human glioblastoma xenograft - Control 47.3151890
GSM967856U87-EV human glioblastoma xenograft - Control 57.0870189
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2454586
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.5523487
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8566688
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6587987
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8723988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.740888
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2528390
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.9321388
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9986189